Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease

Joana Torres, Ray K. Boyapati*, Nicholas A. Kennedy, Edouard Louis, Jean Frédéric Colombel, Jack Satsangi

*Autor correspondente para este trabalho

Resultado de pesquisarevisão de pares

168 Citações (Scopus)


Little is known about the optimal duration of therapy with an anti-tumor necrosis factor (TNF) agent and/or an immunomodulator for patients with inflammatory bowel disease (IBD). We performed a systematic search of the literature to identify studies reporting after de-escalation (drug cessation or dose reduction) of anti-TNF agents and/or immunomodulators in patients in remission from IBD. Studies were reviewed according to the type of IBD and drug. Rates of relapse, factors associated with relapse, and response to re-treatment were determined. Our search yielded 6315 unique citations; we analyzed findings from 69 studies (18 on de-escalation [drug cessation or dose reduction] of immunomodulator monotherapy, 8 on immunomodulator de-escalation from combination therapy, and 43 on de-escalation of anti-TNF agents, including 3 during pregnancy) comprising 4672 patients. Stopping immunomodulator monotherapy after a period of remission was associated with high rates of relapse in patients with Crohn's disease or ulcerative colitis (approximately 75% of patients experienced a relapse within 5 years after therapy was stopped). Most studies of patients with Crohn's disease who discontinued an immunomodulator after combination therapy found that rates of relapse did not differ from those of patients who continued taking the drug (55%-60% had disease relapse 24 months after they stopped taking the immunomodulator). The only study in patients with ulcerative colitis supported continued immunomodulator use. Approximately 50% of patients who discontinued anti-TNF agents after combination therapy maintained remission 24 months later, but the proportion in remission decreased with time. Markers of disease activity, poor prognostic factors, and complicated or relapsing disease course were associated with future relapse. In conclusion, based on a systematic review, 50% or more of patients with IBD who cease therapy have a disease relapse. Further studies are required to accurately identify subgroups of patients who are good candidates for discontinuation of treatment. The decision to withdraw a drug should be made for each individual based on patient preference, disease markers, consequences of relapse, safety, and cost.

Idioma originalEnglish
Páginas (de-até)1716-1730
Número de páginas15
Número de emissão7
Estado da publicaçãoPublicado - 1 dez. 2015
Publicado externamenteSim

Impressão digital

Mergulhe nos tópicos de investigação de “Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease“. Em conjunto formam uma impressão digital única.